Number of shares issued for each share of convertible preferred stock that is converted.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Name:	us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

License agreement with Silo Pharma Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Apr. 12, 2021	Jun. 30, 2021	Jan. 29, 2021
License agreement with Silo Pharma Inc. (Details) [Line Items]
Exchange shares	500
Nonrefundable cash payment (in Dollars)		$ 0.5
Net sales percentage		2.00%	8.00%
Series M Convertible Preferred Stock [Member]
License agreement with Silo Pharma Inc. (Details) [Line Items]
Aggregate of restricted shares	625,000
Par value (in Dollars per share)	$ 0.001